Validation Data Gallery
|Positive WB detected in||mouse colon tissue, HeLa cells, A2780 cells, HepG2 cells|
|Positive IHC detected in||human breast cancer tissue, human colon cancer tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Positive IF detected in||HeLa cells|
|Western Blot (WB)||WB : 1:200-1:1000|
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Immunofluorescence (IF)||IF : 1:10-1:100|
|Sample-dependent, check data in validation data gallery|
10189-2-AP targets IGFBP3 in WB, IHC, IF, ELISA applications and shows reactivity with human, mouse samples.
|Tested Reactivity||human, mouse|
|Cited Reactivity||human, mouse, rat, chicken|
|Host / Isotype||Rabbit / IgG|
|Immunogen||IGFBP3 fusion protein Ag0242|
|Full Name||insulin-like growth factor binding protein 3|
|Calculated molecular weight||32 kDa|
|Observed molecular weight||32-37 kDa|
|GenBank accession number||BC000013|
|Gene ID (NCBI)||3486|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
Insulin-like growth factor binding protein-3 (IGFBP-3) contains a 27 amino acid putative signal sequence followed by a mature protein of 264 amino acids with 18 cysteine residues clustered near the N- and C-terminus. Accordingly, expression of the cloned IGFBP-3 cDNA in mammalian tissue culture cells results in secretion of the protein into the culture medium. IGFBP-3 shares high homology (33% amino acid identity) including conservation of all 18 cysteine residues with a smaller human IGF-binding protein (BP-28) identified in amniotic fluid. IGFBP-3 has one or more glycosylation sites with a protein core of ∼30 kDa. Western blots revealed that the 39-45 kDa IGFBP-3 fragment is a glycoprotein. (PMID: 23403918, PMID: 24926947, PMID: 19887447)
Acta Physiol (Oxf)
Podocyte apoptosis in diabetic nephropathy by BASP1 activation of the p53 pathway via WT1.
Environ Toxicol Pharmacol
Protective potential of epigallocatechin-3-gallate against benign prostatic hyperplasia in metabolic syndrome rats.
Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects.
Downregulation of LOX promotes castration-resistant prostate cancer progression via IGFBP3.
Int J Oncol
Polyphyllin I inhibits invasion and epithelial-mesenchymal transition via CIP2A/PP2A/ERK signaling in prostate cancer.
Stem Cell Res
Normoxia is not favorable for maintaining stemness of human endothelial progenitor cells.